tiprankstipranks
Trending News
More News >
Shanghai Fosun Pharmaceutical (Group) Co Class H (HK:2196)
:2196
Hong Kong Market

Shanghai Fosun Pharmaceutical (Group) Co (2196) Income Statement

Compare
2 Followers

Shanghai Fosun Pharmaceutical (Group) Co Income Statement

Last quarter (Q1 2025), Shanghai Fosun Pharmaceutical (Group) Co's total revenue was ¥9.42B, a decrease of -7.26% from the same quarter last year. In Q1, Shanghai Fosun Pharmaceutical (Group) Co's net income was ¥764.76M. See Shanghai Fosun Pharmaceutical (Group) Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
¥ 41.07B¥ 41.40B¥ 43.95B¥ 39.01B¥ 30.31B
Gross Profit
¥ 19.70B¥ 19.68B¥ 20.78B¥ 18.78B¥ 16.88B
Operating Expenses
¥ 15.46B¥ 16.50B¥ 17.15B¥ 16.06B¥ 14.05B
Depreciation and Amortization
¥ 3.00B¥ 2.97B¥ 2.34B¥ 1.83B¥ 1.67B
EBITDA
¥ 8.60B¥ 7.55B¥ 7.87B¥ 8.70B¥ 6.89B
Operating Income
¥ 4.25B¥ 3.31B¥ 8.30B¥ 6.31B¥ 4.72B
Other Income/Expenses
¥ -75.82M¥ -42.94M¥ -82.27M¥ -259.90M¥ -43.30M
Pretax Income
¥ 4.17B¥ 3.26B¥ 4.57B¥ 6.05B¥ 4.68B
Net Income
¥ 2.77B¥ 2.39B¥ 3.73B¥ 4.73B¥ 3.66B
Per Share Metrics
Basic EPS
¥ 1.04¥ 0.89¥ 1.43¥ 1.85¥ 1.43
Diluted EPS
¥ 1.04¥ 0.89¥ 1.43¥ 1.85¥ 1.43
Weighted Average Shares Outstanding
2.67B 2.68B 2.61B 2.56B 2.56B
Weighted Average Shares Outstanding (Diluted)
2.67B 2.67B 2.61B 2.56B 2.56B
Currency in CNY

Shanghai Fosun Pharmaceutical (Group) Co Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis